High demand for COVID-19 diagnostics driven by the delta variant has led to rocketing sales at Roche's diagnostics division, allowing the company to raise its sales forecast for the year.
AstraZeneca said this morning that it has made $1.2 billion in sales from its COVID-19 vaccine Vaxzevria in the first half of this year, but making it available at no profit had weighed on
The UK's competition regulator has approved AstraZeneca's $39 billion acquisition of US-based drugmaker Alexion, without opting for a broader inquiry into the deal.
Pfizer expects revenues from its BioNTech-partnered COVID-19 vaccine to reach an eye-watering $26 billion this year, catapulting it to the top of the world's biggest-selling medicines.
DNA testing company 23andMe has signed a deal to merge with a ‘blank cheque’ company set up by Virgin billionaire Sir Richard Branson as a shortcut to a public listing.
AstraZeneca has completed the sell-off of another mature product, hiving off its Atacand cardiovascular franchise to Cheplapharm as it continues to slim down and invest in its pipeline.